Bioequivalence and Phase I Studies

Blueclinical provides highly-customized and fully-compliant services, to maximize client’s competitiveness and time-to-market.

Therapeutic Endpoint Studies

Blueclinical has an established partnership with eleven hospitals (Clinical Research Partnership, CRP). Our CRCs help clinical investigators to concentrate on patient recruitment, promoting study success and clinical data quality.

Regulatory Affairs and Pharmacovigilance

Blueclinical provides comprehensive regulatory and pharmacovigilance services from the early stage of development through to marketing of your medicinal products and medical devices.

Translational Medicine Consultancy

Blueclinical provides consultancy services to help you move quickly and effectively your projects from bench to bedside.

About Us

Blueclinical is a privately owned independent full-service CRO

focused on bioequivalence and early-stage clinical studies in healthy subjects and patients, translational medicine consultancy, and site management.

more about us more about our services

Participantes

A Blueclinical está a implementar vários ensaios clínicos em participantes saudáveis.

Informação sobre ensaios clínicos e sobre a forma de candidatura a participação pode ser encontrada na página dos participantes.

Participantes

News

Clinical Trial - Alzheimer's Disease

ULSM (Unidade Local de Saúde de Matosinhos) is currently conducting an Alzheimer's Disease Clinical Trial. For more informations, please contact: crpulsm@blueclinical.pt | 910 016 380

February, 2019

Press Release - Viedoc

Blueclinical Expands Business with Viedoc to Accelerate Bioequivalence and Early-Stage Clinical Studies

January, 2017

Blueclinical has been accredited by the French authorities to Crédit Impôt Recherche.

We are pleased to announce that Blueclinical has been accredited by the French authorities to Crédit Impôt Recherche. As such, French companies carrying out research activities with Blueclinical have a significant competitive advantage: tax credit of 30% of the value of the investment made.

More News